Home » Stocks » Agenus

Agenus Inc. (AGEN)

Stock Price: $3.75 USD 0.44 (13.29%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $3.74 -0.01 (-0.27%) Aug 7, 6:51 PM

Stock Price Chart

Key Info

Market Cap 636.66M
Revenue (ttm) 96.51M
Net Income (ttm) -170.84M
Shares Out 174.74M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $3.75
Previous Close $3.31
Change ($) 0.44
Change (%) 13.29%
Day's Open 3.34
Day's Range 3.34 - 3.83
Day's Volume 3,341,124
52-Week Range 1.82 - 4.79

More Stats

Market Cap 636.66M
Enterprise Value 573.84M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 174.74M
Float 96.07M
EPS (basic) -1.24
EPS (diluted) -1.23
FCF / Share -0.92
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 20.51M
Short Ratio 8.19
Short % of Float 13.94%
Beta 1.92
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 6.60
PB Ratio n/a
Revenue 96.51M
Operating Income -125.14M
Net Income -170.84M
Free Cash Flow -133.57M
Net Cash 62.83M
Net Cash / Share 0.37
Gross Margin -18.95%
Operating Margin -129.66%
Profit Margin -200.60%
FCF Margin -138.40%
ROA -36.72%
ROE n/a
ROIC 258.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$5.50*
(46.67% upside)
Low
5.00
Current: $3.75
High
6.00
Target: 5.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue15036.7842.8822.5724.826.983.0515.962.763.36
Revenue Growth307.92%-14.21%89.95%-9.04%255.67%129.13%-80.92%479.17%-17.97%-
Gross Profit15036.7842.8822.5724.826.982.5115.292.763.24
Operating Income-64.33-125-107-106-74.00-36.62-24.98-6.74-19.09-21.75
Net Income-108-160-121-127-87.88-42.49-30.07-11.32-23.28-21.91
Shares Outstanding13511198.4287.0778.2159.7529.7723.6319.9016.11
Earnings Per Share-0.80-1.44-1.23-1.46-1.13-0.71-1.12-0.51-1.21-1.41
Operating Cash Flow-18.68-131-94.23-79.96-47.18-38.23-19.531.01-16.25-14.76
Capital Expenditures-4.66-3.59-3.00-12.52-3.59-2.82-0.81-0.10-0.03-0.08
Free Cash Flow-23.34-135-97.23-92.48-50.77-41.05-20.350.91-16.28-14.84
Cash & Equivalents61.8153.0560.1976.4417240.2227.3521.4710.7519.78
Total Debt23.3913.361631311146.038.8735.9232.9234.20
Net Cash / Debt38.4239.70-103-54.2557.2034.2018.49-14.45-22.18-14.41
Assets15513613815724274.5334.8429.0919.8130.91
Liabilities38731121419617251.5139.3246.6940.6445.61
Book Value-225-172-75.82-39.1370.7323.02-4.48-23.18-26.41-14.71
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Agenus Inc.
Country United States
Employees 328
CEO Garo H. Armen

Stock Information

Ticker Symbol AGEN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AGEN
IPO Date February 4, 2000

Description

Agenus Inc., a clinical-stage immuno-oncology company, engages in advancing a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Further, it develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bifunctional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. Additionally, the company engages in the development INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390 ? an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.